Clinical Trial Search

Primary: Mean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over Entire DBT Phase (Weeks 1 to 12) — -2.9; -4.0; -2.2 Days per month — p==0.0220

Primary: Mean Feasibility of Intervention Measure (FIM) Score Assessed for SSPs — 4.37; 4.27 Scores on a scale

Primary: Visual Analogue Scale (VAS) Scores of the Tooth Sensitivity Questionnaire Collected Through the Study — 33.8; 41.6; 36.9; 31.1 millimeter

Primary: Total Opioid Use — 0.0; 0.0 mg

Primary: Cure (Clinical Improvement Defined as Reduce of Pain, Bleeding and no Fever for 48h) — 94.06; 86.14 percentage of cure — p=0.06

Primary: Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference 4a Between Week 6 (T2) to Week 15 (T3) — -0.9; -1.8; -1.6; -2.0 score on a…

Primary: Pain Score Change — 4; 2 units on a scale

Primary: Presence of RGV (Residual Gastric Volume) in Stomach — 7; 1 Participants

Primary: Assessment of Seroconversion, Defined as Development of Immunoglobulin G (IgG) Antibodies Against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) After…

Primary: Placebo-controlled Period: Change From Baseline in the Number of MMDs at Weeks 1 - 4 — -6.85; -3.66 days/month — p=<0.0001

Primary: Maximum Observed Concentration (Cmax) of BMS-986165 and BMT-153261 in Breast Milk — 211.0; 74.09 ng/mL

Primary: Occurrence (Yes/No) of NK (K+ Between 3.5 and 5.0 mmol/L, Inclusive) at 180 Days Post-discharge — 21; 25; 47; 44 Number of participants — p=0.558

Primary: Self Reported Reduction in Average Cigarettes Smoked Per Day at 12 Weeks — 5.2; 4.9 cigarettes per day

Primary: Evaluate the Immunogenicity Associated With Daily Subcutaneous (SC) Metreleptin Treatment in Patients With Congenital Generalized Lipodystrophy (CGL) or Acquired…

Primary: Psoriatic Arthritis Disease Activity Score (PASDAS) — 4.7; 4.0; 3.6 score on a scale